TY - JOUR
T1 - Frailty in heart transplantation
T2 - Report from the heart workgroup of a consensus conference on frailty
AU - the Heart Frailty Workgroup
AU - Kobashigawa, Jon
AU - Shah, Palak
AU - Joseph, Susan
AU - Olymbios, Michael
AU - Bhat, Geetha
AU - Dhital, Kumud
AU - Eisen, Howard
AU - Kransdorf, Evan
AU - Patel, Jignesh
AU - Skorka, Rafael
AU - Pinney, Sean
AU - Wilson, Michael E.
AU - Hall, Shelley
N1 - Funding Information:
The authors of this manuscript have conflicts of interest to disclose as described by the . Jon Kobashigawa, MD, is a scientific medical advisor to TransMedics Inc and Novartis. Palak Shah, MD, MS, is a consultant for NuPulse CV and Ortho Clinical Diagnostics and reports grant support from the American Heart Association/Enduring Hearts and Merck. Jignesh Patel, MD, PhD, has received research support from Alexion Pharmaceuticals. American Journal of Transplantation
Publisher Copyright:
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons
PY - 2021/2
Y1 - 2021/2
N2 - A consensus conference on frailty in solid organ transplantation took place on February 11, 2018, to discuss the latest developments in frailty, adopt a standardized approach to assessment, and generate ideas for future research. The findings and consensus of the Frailty Heart Workgroup (American Society of Transplantation's Thoracic and Critical Care Community of Practice) are presented here. Frailty is defined as a clinically recognizable state of increased vulnerability resulting from aging-associated decline in reserve and function across multiple physiologic systems such that the ability to cope with every day or acute stressors is compromised. Frailty is increasingly recognized as a distinct biologic entity that can adversely affect outcomes before and after heart transplantation. A greater proportion of patients referred for heart transplantation are older and have more complex comorbidities. However, outcomes data in the pretransplant setting, particularly for younger patients, are limited. Therefore, there is a need to develop objective frailty assessment tools for risk stratification in patients with advanced heart disease. These tools will help to determine appropriate recipient selection for advanced heart disease therapies including heart transplantation and mechanical circulatory support, improve overall outcomes, and help distinguish frailty phenotypes amenable to intervention.
AB - A consensus conference on frailty in solid organ transplantation took place on February 11, 2018, to discuss the latest developments in frailty, adopt a standardized approach to assessment, and generate ideas for future research. The findings and consensus of the Frailty Heart Workgroup (American Society of Transplantation's Thoracic and Critical Care Community of Practice) are presented here. Frailty is defined as a clinically recognizable state of increased vulnerability resulting from aging-associated decline in reserve and function across multiple physiologic systems such that the ability to cope with every day or acute stressors is compromised. Frailty is increasingly recognized as a distinct biologic entity that can adversely affect outcomes before and after heart transplantation. A greater proportion of patients referred for heart transplantation are older and have more complex comorbidities. However, outcomes data in the pretransplant setting, particularly for younger patients, are limited. Therefore, there is a need to develop objective frailty assessment tools for risk stratification in patients with advanced heart disease. These tools will help to determine appropriate recipient selection for advanced heart disease therapies including heart transplantation and mechanical circulatory support, improve overall outcomes, and help distinguish frailty phenotypes amenable to intervention.
KW - clinical research/ practice
KW - heart disease
KW - heart disease: metabolic
KW - heart failure/ injury
KW - heart transplantation/ cardiology
UR - http://www.scopus.com/inward/record.url?scp=85089957678&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089957678&partnerID=8YFLogxK
U2 - 10.1111/ajt.16207
DO - 10.1111/ajt.16207
M3 - Article
C2 - 32659872
AN - SCOPUS:85089957678
SN - 1600-6135
VL - 21
SP - 636
EP - 644
JO - American Journal of Transplantation
JF - American Journal of Transplantation
IS - 2
ER -